-
2021 CCO Prof. Ye Dingwei: Prostate cancer, between East and West
Time of Update: 2022-06-15
Professor Ye Dingwei pointed out that in order to break through the dilemma of prostate cancer, it is necessary to navigate between China and the West, make good use of the "troika" of early screening, precise treatment and multidisciplinary participation, and embark on a road of innovation .
-
CACA Guidelines for Screening and Early Diagnosis of Prostate Cancer Patients
Time of Update: 2022-06-15
CACA guidelines recommend the following methods for the diagnosis of prostate cancer: digital rectal examination (DCE) in physical examination, PSA test in laboratory examination, magnetic resonance imaging (MRI), and needle biopsy .
-
Integrated diagnosis and treatment of early prostate cancer patients according to CACA guidelines
Time of Update: 2022-06-14
During the 2021 CCO conference, the intensive reading conference of "China Integrated Tumor Diagnosis and Treatment Guidelines-Prostate Cancer" was held online . At the meeting, combined with the
-
Hit the wall again!
Time of Update: 2022-06-13
The final study results showed that the addition of checkpoint inhibitors did not further improve overall survival (OS) in patients with mCRPC compared to endocrine therapy with androgen receptor blockers alone, but the broad biomarker analysis relevant to this study was Further exploration of predictive biomarkers of ICIs in mCRPC brings new thinking.
-
CACA Guidelines for Clinical Management of Patients with Advanced Prostate Cancer
Time of Update: 2022-06-13
The successful diagnosis and treatment of this patient fully demonstrates that for patients with advanced metastatic prostate cancer, multi-drug combination and timely local treatment can still achieve the purpose of prolonging the patient's survival time and improving the patient's quality of life .
-
Inconsistent effects of neoadjuvant chemotherapy?
Time of Update: 2022-06-12
74, Table 2) Table 2 Results of univariate and multivariate analysis of the effect of NAC treatment and molecular subtype on patients' OS The results of CSS were similar to those of OS, for patients with luminal subtype , receiving NAC or not was not associated with improved clinical benefit of CSS; patients with non-luminal subtype receiving NAC improved CSS by 11% at 3 years (77% vs 66% Figure 3C-D) .
-
2021 CCO CACA Guidelines: Screening and early diagnosis of prostate cancer patients
Time of Update: 2022-06-12
CACA guidelines recommend the following methods for the diagnosis of prostate cancer: digital rectal examination (DCE) in physical examination, PSA test in laboratory examination, magnetic resonance imaging (MRI), and needle biopsy .
-
This cancer should be "removed"?
Time of Update: 2022-06-10
Removing low-risk lesions from prostate cancer may significantly reduce overdiagnosis and overtreatment of prostate cancer and improve the cost-effectiveness of PSA screening .
Removing such clinically low-risk lesions from prostate cancer may eliminate patient fears, significantly reduce overtreatment of prostate cancer, and significantly increase the cost-benefit of PSA screening .
-
Professor He Zhisong, the new "cyst" Jing, talks about the advantages of adjuvant immunotherapy for urothelial carcinoma
Time of Update: 2022-06-08
*This article is only used to provide scientific information to medical professionals and does not represent the views of this platformFirst results from the phase 3 CheckMate 274 trial of adjuvant nivolumab versus placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma, Oral presentation at the 2021 Genitourinary Cancers Symposium (ASCO GU); February 11–13, 2021; Virtual Meeting.
-
"Philippines" long field of view - exploring the efficacy of different LHRHas in prostate cancer when Shuowen Jiejie is in progress
Time of Update: 2022-06-08
Therefore, a Korean retrospective study evaluated the efficacy of triptorelin, goserelin, and leuprolide in advanced/metastatic prostate cancer (change in testosterone level and change in chemical castration rate), providing clinical information for clinical use reference .
-
A new era of "combination therapy" for prostate cancer is here!
Time of Update: 2022-06-06
Feature 2: Emphasis on specific subtypes, precise specification and emphasis Professor Ye Dingwei said: "This "Guideline" update pays attention to the treatment of intraductal carcinoma and neuroendocrine differentiated carcinoma with poor prognosis, the standardized detection and treatment of HRR mutation patients, and the importance of The diagnostic and therapeutic value of PSMA in prostate cancer .
-
Li Zhenfei/Wu Denglong/Huang Shengsong's team identified a new target for advanced prostate cancer treatment Cell Press Dialogue with Scientists
Time of Update: 2022-06-06
Finally, the researchers demonstrated through different clinical trials that the metabolic enzyme 3βHSD1 is a more suitable therapeutic target for advanced prostate cancer in the Chinese population; its inhibitors can prevent disease progression in abiraterone-resistant patients .
-
Secondary refractory hematuria and urinary retention in patients with advanced prostate cancer?
Time of Update: 2022-06-06
Image of a 76-year-old male patient with advanced prostate cancer-related RGH Patient Follow-up Patients underwent clinical, biochemical, and MRI follow-up at 1, 3, 6, and 12 months after treatment .
-
PSA deep and rapid decline, OS for a long time "K" period, advanced prostate cancer with multiple bone metastases, apalutamide + ADT brings PSA deep response, long-term tumor control effect is obvious classic case
Time of Update: 2022-06-05
During the patient's treatment, the symptoms related to bone metastases and primary lesions were significantly improved, highlighting the excellent efficacy and safety of ADT + apalutamide combination therapy .
-
Secondary refractory hematuria and urinary retention in patients with advanced prostate cancer?
Time of Update: 2022-06-05
Image of a 76-year-old male patient with advanced prostate cancer-related RGH Patient Follow-up Patients underwent clinical, biochemical, and MRI follow-up at 1, 3, 6, and 12 months after treatment .
-
Bladder enlargement + ureteral replantation?
Time of Update: 2022-06-01
Introduction There is controversy about whether patients should undergo simultaneous ureteral reimplantation and bladder enlargement in the treatment of vesicoureteral reflux (VUR) secondary to neurogenic bladder .
A study exploring the need for simultaneous bladder enlargement and ureteral reimplantation in patients with VUR secondary to neurogenic bladder was published in BMC Urology .
-
The latest data of Arvinas androgen receptor PROTAC therapy show sustained anti-tumor activity
Time of Update: 2022-05-03
February 21, 2022/eMedClub PR News/--On February 17, 2022, Arvinas, a clinical-stage biotechnology company, announced the completion of bavdegalutamide, a novel PROTAC® protein degrader targeting the androgen receptor (AR).
-
Express continues to improve the survival of bladder cancer patients, and the long-term efficacy of the German Merck/Pfizer PD-L1 inhibitor is gratifying
Time of Update: 2022-05-03
At a median follow-up of 38 months, the combination of Bavencio as first-line maintenance therapy and BSC improved median overall survival (OS) in patients with locally advanced or metastatic UC compared with best supportive care (BSC) alone ) was extended by 8.
-
What are the types of prostatitis and how are they treated?
Time of Update: 2022-05-02
Chronic bacterial prostatitis: Usually the same cause as acute bacterial infection .
Alpha-blockers are commonly used in men with chronic prostatitis/chronic pelvic pain syndrome, but are sometimes used to relieve urinary symptoms caused by bacterial infections .
-
Prostate cancer should be checked at age?
Time of Update: 2022-05-02
Considering the impact of prostate cancer screening on people's quality of life and length of life, and the condition of most prostate cancer patients The development is relatively slow, and the "Guidelines" recommend that for high-risk groups under the age of 75 and with a life expectancy of more than 10 years, the first screening test using serum prostate-specific antigen (PSA) test is performed every two years .
